Point mutation of C-terminal region of CD20 molecule predicts rituximab-induced complement-dependent cytotoxicity and clinical response to rituximab in non-Hodgkin's lymphoma.

被引：0
|
作者：
Terui, Y.
Mishima, Y.
Mishima, Y.
Yokoyama, M.
Hatake, K.
Sugimura, N.
Kojima, K.
Sakurai, T.
Takeuchi, K.
机构：
[1] CIH, Tokyo, Japan
[2] Morinaga Milk Co, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：437S / 437S
页数：1
相关论文
共 47 条
  • [21] Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haematolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.
    Bauduer, F
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (04) : 1085 - 1086
  • [22] CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma
    Cruz, Raymond I.
    Hernandez-Ilizaliturri, Francisco J.
    Olejniczak, Scott
    Deeb, George
    Knight, Joy
    Wallace, Paul
    Thurberg, Beth L.
    Kennedy, William
    Czuczman, Myron S.
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2424 - 2436
  • [23] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Kensei Tobinai
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S85 - S90
  • [24] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Tobinai, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S85 - S90
  • [25] Targeting CD20 and CD22 with rituximab in combination with CMC-544 results in improved anti-tumor activity against non-Hodgkin's lymphoma (NHL) pre-clinical models.
    Hernandez-Ilizaliturri, FJ
    Devineni, S
    Arora, S
    Knight, J
    Czuczman, MS
    BLOOD, 2005, 106 (11) : 425A - 425A
  • [26] Radioimmunotherapy in relapsed or refractory B-cell non-hodgkin's lymphoma with I-131-labeled chimericanti CD20 C2B8 (I-131 rituximab)
    Kang, H. J.
    Park, Y. H.
    Kim, S.
    Cheon, G. J.
    Choi, C. W.
    Lim, S. M.
    Lee, S. S.
    Na, I. I.
    Ryoo, B. Y.
    Yang, S. H.
    Kim, W. S.
    Kim, K. H.
    Bang, S. M.
    Yuh, Y. J.
    Nam, S. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 108 - 109
  • [27] Characterization of new, chimeric and humanized, anti-CD20 monoclonal antibodies, cA20 and hA20, with equivalent efficacy to rituximab in-vitro and in xenografted human non-Hodgkin's lymphoma.
    Goldenberg, DM
    Li, XG
    Qu, ZX
    Stein, R
    Horak, ID
    Hansen, HJ
    BLOOD, 2002, 100 (11) : 575A - 576A
  • [28] IMMUNOTHERAPY WITH RITUXIMAB (RITUXAN)/INTERLEUKIN 2 (IL-2) FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN'S LYMPHOMA
    Holmberg, L. A.
    Maloney, D. G.
    Bensinger, W., I
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 39 - 39
  • [29] IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
    Maloney, DG
    GrilloLopez, AJ
    White, CA
    Bodkin, D
    Schilder, RJ
    Neidhart, JA
    Janakiraman, N
    Foon, KA
    Liles, TM
    Dallaire, BK
    Wey, K
    Royston, I
    Davis, T
    Levy, R
    BLOOD, 1997, 90 (06) : 2188 - 2195
  • [30] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Klemens Scheidhauer
    Ingo Wolf
    Hans-Joachim Baumgartl
    Christoph von Schilling
    Burkhard Schmidt
    Günther Reidel
    Christian Peschel
    Markus Schwaiger
    European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29 : 1276 - 1282
12345